Free Trial
NASDAQ:PMCB

PharmaCyte Biotech 9/16/2024 Earnings Report

PharmaCyte Biotech logo
$1.00 -0.02 (-2.17%)
As of 06/13/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

PharmaCyte Biotech EPS Results

Actual EPS
$0.14
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

PharmaCyte Biotech Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

PharmaCyte Biotech Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

PharmaCyte Biotech's next earnings date is estimated for Monday, August 11, 2025, based on past reporting schedules.

Conference Call Resources

PharmaCyte Biotech Earnings Headlines

[Wanted] 250 intrepid souls
He Called this 106X Opportunity Before Reddit… and Before Elon Musk Before GameStop rocketed up to 10,633, Jonathan Rose saw something strange: A sudden surge in options volume — thousands of contracts flooding in. The money hit deep inside the CBOE before Reddit posts created the short squeeze and before Elon's tweet sent GameStop flying. Jonathan calls it the "Big-Money Tell," and it's flagged dozens of big trade opportunities including: 462.5% in C3.ai, 245.13% in Criteo, and 39.46% in Roku. And these are just some of the gains the "tell" has identified. Even better: He says the next big set-up could be forming right now. And there's still time for you to get in before it kicks off as soon as seven days from now.
PharmaCyte Biotech Inc PMCB
See More PharmaCyte Biotech Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like PharmaCyte Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PharmaCyte Biotech and other key companies, straight to your email.

About PharmaCyte Biotech

PharmaCyte Biotech (NASDAQ:PMCB), a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte. Ltd. and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.

View PharmaCyte Biotech Profile

More Earnings Resources from MarketBeat